HYDROMETHYLTHIONINE DIHYDROBROMIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H19N3S.2BrH
Molecular Weight	447.231
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of HYDROMETHYLTHIONINE DIHYDROBROMIDE

Structure Search

SMILES

Br.Br.CN(C)C1=CC2=C(NC3=C(S2)C=C(C=C3)N(C)C)C=C1

InChI

InChIKey=JAUPSVVTGFBHTN-UHFFFAOYSA-N

InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H

HIDE SMILES / InChI

Molecular Formula	C16H19N3S
Molecular Weight	285.407
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://taurx.com/lmtx-for-alzheimers.html | https://clinicaltrials.gov/ct2/show/NCT03446001 | https://www.ncbi.nlm.nih.gov/pubmed/25759392

L-MTX is a second-generation tau protein aggregation inhibitor. It acts by reducing levels of aggregated or misfolded tau proteins, which are associated with the progressive neurodegeneration. It is currently under development for the treatment of Alzheimer’s disease.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tau protein aggregation 3 Target ID: Tau protein aggregation Sources: https://www.ncbi.nlm.nih.gov/pubmed/26809554\|http://taurx.com/lmtx-for-alzheimers.html\|https://www.ncbi.nlm.nih.gov/pubmed/25759392	Inhibitor 8297		0.12 µM [Ki]

PubMed

Title	Date	PubMed
Tau-aggregation inhibitor therapy for Alzheimer's disease.	2014 Apr 15	24361915
Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.	2015 Apr 24	25759392
Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.	2016 Dec 10	27863809

Patents

Sample Use Guides

In Vivo Use Guide

L-MTX is given as a monotherapy at doses of 8 mg/day (taken as 4 mg twice daily) and of 16 mg/day (taken as 8 mg twice daily).

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:50:42 GMT 2023` Edited by `admin` on `Sat Dec 16 11:50:42 GMT 2023`
Record UNII	E79ZM68IOZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HYDROMETHYLTHIONINE DIHYDROBROMIDE

Common Name

English

N3,N3,N7,N7-TETRAMETHYL-10H-PHENOTHIAZINE-3,7-DIAMINE DIHYDROBROMIDE

Systematic Name

English

REDUCED METHYLENE BLUE DIHYDROBROMIDE

Common Name

English

LEUCOMETHYLENE BLUE DIHYDROBROMIDE

Common Name

English

LEUKOMETHYLENE BLUE DIHYDROBROMIDE

Common Name

English

Code System Code Type Description

FDA UNII

E79ZM68IOZ